Assessment of Metformin as an Additional Treatment to Therapeutic Lifestyle Changes in Pediatric Patients with Metabolic Syndrome. (4th July 2012)

• Record Type: Journal Article
• Authors: Raub, Rebecca M.; Goldberg, Stanley J.
• Other Names: Kelishadi Roya Academic Editor.
• Is Part Of: Cholesterol. Volume 2012(2012)
• Publication Date: 2012-07-04
• Subjects: Cholesterol -- Periodicals; Cholesterol -- Metabolism -- Periodicals; Cholesterol -- Health aspects -- Periodicals; Coronary heart disease -- Prevention -- Periodicals; 612.0157705
• DOI: 10.1155/2012/961410
• Languages: English
• ISSNs: 2090-1283

Abstract

Abstract : Objective . To assess the effectiveness of metformin and therapeutic lifestyle changes (TLCs) in a clinical setting, compared to TLC alone in adolescents with metabolic syndrome (MS). Methodology . This study was a retrospective trial consisting of 60 patients, aged 8–18 years, who were treated for MS at an outpatient clinic. Two groups were formed: the metformin group (M group) and the control group (C group). The M group had been given metformin along with TLC, and the C group had been given TLC alone. Several outcome measures were obtained; the main outcome measure was measuring the change in percentile and z-score of weight and BMI. Results . There were no significant differences between the two groups at the conclusion of the study, except for height percentile (P = 0.02 ) and z-score (P = 0.03 ). Both groups showed promising significant intragroup decreases in weight z-score but BMI percentile and z-score were only significantly decreased in the M group. Conclusion . Metformin at an average dose of 1033 mg, when added to TLC, did not show any clinically important efficacy compared to TLC alone in a pediatric population with MS. However, both groups made significant changes in a positive direction, which may be solely due to TLC.